Repurposing Kir6/SUR2 Channel Activator Minoxidil to Arrests Growth of Gynecologic Cancers.

Gynecologic cancers are among the most lethal cancers found in women, and, advanced stage cancers are still a treatment challenge. Ion channels are known to contribute to cellular homeostasis in all cells and mounting evidence indicates that ion channels could be considered potential therapeutic targets against cancer. Nevertheless, the pharmacologic effect of targeting ion channels in cancer is still understudied.

Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer.

Potassium ion (K) channels have been recently found to play a critical role in cancer biology. Despite that pharmacologic manipulation of ion channels is recognized as an important therapeutic approach, very little is known about the effects of targeting of K channels in cancer. In this study, we demonstrate that use of the Kv11.

Comparison of the Beckman TL-100 ultracentrifuge with the Amicon Centrifree Micropartition filters to determine protein-free phenytoin concentrations.

Non-protein-bound phenytoin levels obtained by ultracentrifugation (UC) with the Beckman TL-100 desk-top ultracentrifuge were compared with those obtained by ultrafiltration (UF) using the Amicon Centrifree Micropartition device. Total phenytoin concentrations were measured by an enzyme multiplied immunoassay technique (EMIT) adapted to a Cobas Bio centrifugal analyzer, whereas free levels were estimated by a radiometric assay. The following conditions for UC were established: 350,000 g for 1 h, sample volume 250 microliter.